For research use only
| Cat No. | ABC-TC0460 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Product Code | ISTSL1 |
Species: human male; Tissue: lung; Tumor: carcinoma, small cell; Derived from: metastatic lymph node
IST-SL1 is a human small-cell lung carcinoma tumor cell line originally established from a metastatic supraclavicular lymph node of a 60-year-old Caucasian male patient with small-cell lung cancer (SCLC). It exhibits adherent or semi-adherent epithelial-like morphology under standard culture conditions . IST SL1 SCLC cell line is microsatellite stable (MSS). Genomic analysis shows a homozygous splice donor mutation in RB1, a characteristic driver alteration in small-cell lung carcinoma biology. IST-SL1 has been used to investigate interleukin-2 receptor expression and biological effects of IL-2 gene transfection in small-cell lung cancer models, demonstrating its utility in functional signaling studies. As a malignant tumor model, IST-SL1 provides a robust platform for research into tumor cell proliferation and signaling pathways in aggressive lung cancer. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | ISTSL1 |
| Species | Human |
| Cat.No | ABC-TC0460 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
IST-SL1 cells are used as an in vitro human small-cell lung carcinoma model for studying tumor cell proliferation, RB1-associated oncogenic signaling, and cytokine receptor biology (e.g., IL-2). They support drug sensitivity assays, pathway analyses, and preclinical evaluation of therapeutics relevant to aggressive pulmonary neuroendocrine tumors.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
